Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...

Los Angeles Times readers give their thoughts on Bill Plaschke's poignant column on Parkinson's disease, the Dodgers and the ...

Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

If you bought a Freihofer's product over the last two months, you may have helped raise more than $18,000 to benefit the ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Discover how Parkinson's disease begins in the gut, not the brain. Learn the early digestive warning signs that appear years ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Parkinson's disease is a progressive and common neurodegenerative condition, typically characterized by involuntary shaking, ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...